Overview
Exact Sciences Q3 revenue grows 20% yr/yr, beating analyst expectations
Company raises full-year 2025 revenue and adjusted EBITDA guidance midpoints
Exact Sciences launches Cancerguard, a multi-cancer early detection test in the U.S.
Outlook
Exact Sciences raises full-year 2025 revenue guidance to $3.220 - $3.235 bln
Company increases full-year 2025 adjusted EBITDA guidance to $470 - $480 mln
Exact Sciences launches Cancerguard test, potentially boosting future revenue
Result Drivers
SCREENING REVENUE - Screening revenue increased by 22% to $666 mln, driven by Cologuard and PreventionGenetics
PRECISION ONCOLOGY - Precision Oncology revenue grew 13% to $184 mln, supported by Oncotype DX and therapy selection tests
CANCERGUARD LAUNCH - Launched Cancerguard, a multi-cancer early detection test, contributing to growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $850.73 mln | $810.10 mln (22 Analysts) |
Q3 Net Income | -$19.59 mln | ||
Q3 Basic EPS | -$0.10 | ||
Q3 Income From Operations | -$25.54 mln | ||
Q3 Pretax Profit | -$17.75 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Exact Sciences Corp is $68.11, about 5% above its October 31 closing price of $64.69
Press Release: ID:nBwbgt4xXa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)